Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 3/20 | 0.47 |
| ▸ | BMP1 | P13497 | 1/20 | 0.45 |
| ▸ | CTSL | P07711 | 5/20 | 0.41 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.40 |
| ▸ | CCR1 | P32246 | 1/20 | 0.40 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.39 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.36 |
| ▸ | CTSS | P25774 | 2/20 | 0.34 |
| ▸ | CTSK | P43235 | 2/20 | 0.34 |
| ▸ | ANPEP | P15144 | 2/20 | 0.34 |
| ▸ | FPR2 | P25090 | 1/20 | 0.34 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.33 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.33 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.33 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.33 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.33 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4141710 | 0.93 | CAPN1 (0.49) | CAPN1BMP1CTSLTRPV4CCR1 | |
| SCHEMBL4142973 | 0.92 | CAPN1 (0.48) | CAPN1BMP1CTSLTRPV4CCR1 | |
| SCHEMBL5429199 | 0.91 | CAPN1 (0.47) | CAPN1BMP1CTSLTRPV4CCR1 | |
| SCHEMBL4128798 | 0.89 | CAPN1 (0.47) | CAPN1BMP1CTSLTRPV4CCR1 | |
| SCHEMBL4130820 | 0.85 | CAPN1 (0.47) | CAPN1BMP1CTSLTRPV4CCR1 | |
| SCHEMBL5439623 | 0.84 | CAPN1 (0.47) | CAPN1BMP1CTSLTRPV4CCR1 | |
| SCHEMBL4129767 | 0.84 | CAPN1 (0.47) | CAPN1BMP1CTSLTRPV4CCR1 | |
| SCHEMBL4136304 | 0.83 | CAPN1 (0.53) | CAPN1BMP1CTSLTRPV4CCR1 | |
| SCHEMBL4127287 | 0.83 | CAPN1 (0.47) | CAPN1BMP1CTSLTRPV4CCR1 | |
| SCHEMBL5437700 | 0.82 | MEN1 (0.45) | CAPN1BMP1CTSLTRPV4CCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | SMITHKLINE BEECHAM CORPORATION | 2009-04-23 | — | — | US | disclosed |
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | SMITHKLINE BEECHAM CORPORATION | 2009-04-23 | — | — | US | disclosed |
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | SMITHKLINE BEECHAM CORPORATION | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | TRPV4, TRPC4, TRPV1 | CAPN1 2031/4885BMP1 2172/4885CTSL 3815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.